Statistics for Denali Therapeutics (id:7440 DNLI)

Valuation metrics

Market cap

4.09B

Enterprise value

3.48B

Trailing P/E (ttm)

-23.29

Forward P/E

-10.35

PEG ratio

-10.35

Price/Sales (ttm)

12.39

Price/Book (mrq)

3.10

Enterprise Value/Revenue

10.53

Enterprise Value/EBITDA

-6.80

Overview

Shares outstanding

143.92M

Float

130.11M

Shares short

7.43M

% Held by insiders

0.10%

% Held by institutions

0.91%

Average volume (10 days)

916.72K

Average volume (90 days)

Price summary

52-Week low

14.56

52-Week high

33.33

52-Week change

27.34%

Beta

1.39

50-Day moving average

28.14

200-Day moving average

22.32

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

0.00%

Operating margin

-59.51%

Operational effectiveness

Return on assets

-23.81%

Return on equity

-35.09%

Income statement

Revenue (ttm)

2.41

Revenue per share (ttm)

2.41

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

-511,854,016.00

Net income to common (ttm)

-427,492,992.00

Diluted EPS (ttm)

-2.76

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

836.56M

Total cash per share (mrq)

5.81

Total debt (mrq)

52.57M

Total Debt/Equity (mrq)

3.99

Current ratio (mrq)

997.60%

Book value per share (mrq)

9.17

Cash flow

Cash flow statement

-362,636,000.00

Levered free cash flow (LFCF)

-212,806,496.00